The Dutch VC firm Forbion Capital Partners, investing in world-class healthcare technologies, announced that its portfolio company uniQure has closed its initial public offering (IPO) at a price of $17.00 per share. uniQure’s shares are listed on the NASDAQ Global Select Market and began trading under the symbol “QURE“.
Last year Sander van Deventer, partner at Forbion, was one of our speakers at Dutch Innovators in Science & Technology 2013 (DIST 2013) here in Shanghai. During his talk he explained the audience what and how gene therapy can do to combat several rare but severe diseases.
Glybera, one of uniQure’s gene therapies. Photo: nature.com
uniQure is a leader in the field of gene therapy and has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. uniQure is developing a pipeline of additional gene therapies.
Read more: uniQure press release